Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Publications
3 shownConfirmatory interleukin-1 receptor antagonist trial in severe sepsis
A 72-hr, continuous intravenous infusion of rhIL-1ra failed to demonstrate a statistically significant reduction in mortality when compared with standard therapy in this multice...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 7,028
- Institution
- Cornell University
External Links
Identifiers
- ORCID
- 0009-0007-6559-0151
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.